Cat’s Pride introduces lightweight litter formula
CHICAGO — Cat’s Pride, manufactured by Oil-Dri Corp. of America, has announced the newest member of its lightweight litter family, Cat’s Pride Fresh & Light All Day Odor Control. The new scented, multi-cat scoopable litter is up to 40% lighter and has three times longer-lasting odor control than other leading scoopable clay litters, allowing for less frequent changes, the company stated.
"As the leading lightweight litter, Cat’s Pride Fresh & Light is determined to continue meeting the needs of our consumers and help make their cat litter experience better," says Thierry Jean, VP and general manager of the consumer products group of Oil-Dri Corp. of America, which has made Cat’s Pride for more than 60 years. "We are proud to offer a quality product that not only has superior performance, but is much lighter and easier for consumers to lift, carry and use."
Cat’s Pride Fresh & Light All Day Odor Control joins Cat’s Pride family of lightweight litters, including Quick Action and Fragrance-Free Odor Control, both multi-cat litters that are up to 25% lighter than other scoopable clay litters, the company noted. A 15-lb. jug of these litters and a 12-lb. jug of All Day Odor Control provide the same number of uses as 20 lbs. of most other leading scoopable clay brands.
Due to its total odor control and clumping ability, Cat’s Pride Fresh & Light works even when a day is missed, and is a low-dust formula to help prevent litter from tracking, stated Oil-Dri. Available nationwide, 12- and 15-lb. jugs of Cat’s Pride Fresh & Light retail for $8.50-$9.50.
Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.
AstraZeneca buys Md.-based biotech firm
LONDON — AstraZeneca has bought Maryland-based biotech company Amplimmune, the drug maker said.
AstraZeneca announced the acquisition of privately owned Amplimmune through its MedImmune biologics research and development subsidiary, saying it would boost its cancer drug pipeline. Amplimmune’s pipeline includes several experimental treatments, such as AMP-514, a monoclonal antibody currently in preclinical development for which the company hopes to apply to start clinical trials before the end of the year.
"MedImmune’s focus on harnessing the power of the patient’s own immune system to fight cancer will be complemented by Amplimmune’s innovative work in this area," MedImmune EVP Bahija Jallal said. "It will allow us to strengthen our arsenal of potential cancer therapies."
Consumers are shopping smarter across BTS
More than half of viewers indicated they will seek out sales more than they have in past years, according to an online survey of more than 500 AccentHealth viewers conducted in July. As many as 26% reported they would spend more this year, while 1-in-5 plan to buy more preventive products. To see more Patient Views, click here
Patient Views is an exclusive consumer insights feature that appears regularly in DSN magazine, as well as the daily e-newsletter DSN A.M. If you could ask more than 6,000 patients anything at all, what would it be? Send your questions to [email protected].
Source: AccentHealth. To view the demographic breakdown of participants, click here.